Article
FDA Grants Priority Review to Nivolumab Plus Cabozantinib in Advanced RCC
Rating:
0.0
Views:
81
Likes:
1
Library:
1
The FDA has granted a priority review designation to a supplemental biologics license application and supplemental new drug application for nivolumab plus cabozantinib for the treatment of patients with advanced renal cell carcinoma.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value